comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-04 04:25:02 - browse：2396

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Emergency medicine has repudiated 'excited delirium.' Now what?

WSS

NIH confirmation hearing shows politicization of research

Researchers explore possible ties between long Covid, menopause

Physician subsidies by hospitals soar in wake of No Surprises Act

Readout Newsletter: XBI biotech index, Akero Therapeutics

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

FDA gives detailed accounting of AI

focus

comprehensive

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Emergency medicine has repudiated 'excited delirium.' Now what?

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Medical records are filled with copy

Emergency medicine has repudiated 'excited delirium.' Now what?

Continuity nursing helped my family in our darkest PICU moments

Pharmacists can make shortage drugs, but at what cost?

Virginia high school admissions case could be legal follow

Eli Lilly expects to double planned employment in Boston center

focus

Studies point to risks of excluding people with obesity from drug trials

Medicare reduced heart disease by changing how it pays doctors

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

FDA struggles to regulate food additives, sometimes for decades

Will Ozempic

First Opinion Podcast: How to protect health care in times of war

focus

Wikipedia

knowledge

focus